Sanwo-Olu Unveils 500 Mass Transit Buses, Launches Smart Ticketing System

Must Read

List of United Bank for Africa (UBA) Sort Codes & Branches (with addresses) in Nigeria

The sort code is a number that usually identifies both the bank and the branch where an account is held. The sort...

List of Access Bank Sort Codes & Branches (with addresses) in Nigeria

The sort code is a number which usually identifies both the bank and the branch where an account is...

List of First Bank of Nigeria Sort Codes in Nigeria

The sort code is a number that usually identifies both the bank and the branch where an account is held. The sort...
- Advertisement -

All activities literally stood still in Oshodi and Abule Egba axis on Tuesday, for the formal commissioning of the Oshodi-Abule Egba Bus Rapid Mass Transit (BRT) corridor by Lagos State Governor, Mr. Babajide Sanwo-Olu.

The ecstatic crowd of residents filed along the route to welcome the Governor, who rode in a BRT bus to formally flag off the 13.68 kilometre-long corridor for public use.
Sanwo-Olu Unveils 500 Mass Transit Buses, Launches Smart Ticketing System - Brand Spur
The BRT project was handled and supervised by the Lagos Metropolitan Area Transport Authority (LAMATA) – an agency of the State’s Ministry of Transportation.
The Oshodi-Abule Egba corridor is a major link for residents who commute in and out of Alimosho, Egbeda, Ijaiye, Iyana Ipaja and Oshodi. The route is also a gateway to neighbouring Ogun State and Republic of Benin.
Sanwo-Olu Unveils 500 Mass Transit Buses, Launches Smart Ticketing System Sanwo-Olu Unveils 500 Mass Transit Buses, Launches Smart Ticketing System
Governor Sanwo-Olu described the event as “a major milestone” in the implementation of his administration’s reform agenda in the public transport system, pointing out that the handover of the BRT infrastructure was another promise fulfilled by his administration.
Sanwo-Olu Unveils 500 Mass Transit Buses, Launches Smart Ticketing System Sanwo-Olu Unveils 500 Mass Transit Buses, Launches Smart Ticketing System
He said the transportation asset would create a new travel experience for residents of Alimosho and Oshodi, stressing that the project was specifically designed to improve journey time for commuters, thereby scaling up productivity and life expectancy in the State.
He said: “A little over a year ago, we pledged to significantly improve traffic flow and transportation system which is the very first of our six-point development agenda encapsulated as Project T.H.E.M.E.S. We made the pledge knowing that the people are the main reason we have been entrusted with the management of our commonwealth.
Sanwo-Olu Unveils 500 Mass Transit Buses, Launches Smart Ticketing System Sanwo-Olu Unveils 500 Mass Transit Buses, Launches Smart Ticketing System
“Today, we are here to formally flag-off a very important public transport infrastructure – the Oshodi–Abule Egba BRT corridor – which officially launches the commencement of transport operation along the BRT corridor. We are unveiling 550 high and medium capacity buses which will be immediately deployed for public use. This event also formally inaugurates our upgraded e-ticketing system in fulfilment of our pledge.
Sanwo-Olu Unveils 500 Mass Transit Buses, Launches Smart Ticketing System Sanwo-Olu Unveils 500 Mass Transit Buses, Launches Smart Ticketing System
“This project is very significant because of its immense benefits to Lagosians in the different communities it straddles and to visitors to our state. This new BRT corridor will bring great relief to over 60,000 commuters who will use this facility daily. Travel time, which is estimated at an average of two hours during peak periods, will be significantly reduced to an average of 30 minutes. This will improve the health of our people, engender a safer environment, and increase the value of socio-economic activities in the State.”
Sanwo-Olu said his administration’s reform efforts were geared towards birthing a new commuting order in the State through seamless travel and creating smart mobility model that’ll result in a congestion-free State. He reiterated that his Government remained committed to bringing problem-solving interventions across all modes of the transportation sector in Lagos.
To integrate all transport modes on a single smart payment ecosystem, the Governor launched an upgraded e-ticketing platform that would automate fare payment and create smart mobility through a cashless pre-paid Cowry card.
The e-ticketing mechanism has modern functionalities which simplify the process of bus booking and the ticket purchase. It introduces simple solutions that guarantee seamless cash and wireless payment for passengers at designated booths.
The Cowry card will enable passengers to proceed to the loading bay and scan the card for fare deduction.
Sanwo-Olu said: “With the e-ticketing system, we envisage the use of a single card on buses and ferries and later upscale to the railway’s system when passenger operations commence in 2022. The system promotes a cashless ecosystem, aids personal budgeting and planning and commuters can easily top-up.”
The Governor disclosed that the State Government would be distributing the first 100,000 Cowry cards to residents free of charge.
Sanwo-Olu said the State Government was on the verge of complementing Oshodi-Abule Egba BRT corridor with rail project to aid mass mobility.
He hailed LAMATA for supervising the project construction and bringing it to reality, while also thanking President Muhammadu Buhari for supporting the State Government in its drive to deliver an efficient transport system.
He said: “Our administration is very passionate about easing the movement of the citizenry around this beautiful State which is why we would not stop at ensuring that we give you a transport system that works for you.
“I would like to congratulate Lagosians on the successful completion of this project in spite of the challenges thrown up by its implementation. I would also like to commend Lagosians for the pains they had to endure while the construction of this important transport project lasted.”
Commissioner for Transportation, Dr. Frederic Oladehinde, described the project as “great progress” in the public transport system, noting that the BRT route was important to the State’s strategic transportation master plan.
Managing Director of LAMATA, Engr. Abimbola Akinajo said the commencement of BRT operations along the corridor would reduce travel time for commuters by 35 per cent, while also enhancing socio-economic development.
She said: “The frequency of the BRT operation along this route will enhance public transport accessibility by up to 25 per cent, while the provision of the dedicated lane will enhance reliability on the public transportation by 30 per cent. The project has been designed to integrate the proposed Red Line Rail Mass Transit project as part of the Sanwo-Olu administration’s transportation blueprint.”
The new BRT corridor is a median running route with 14 drop-off terminals along the Oshodi-Abule Egba route, which terminates at Katangua Bus Station. Each terminal has well-ventilated foyer where passengers can sit and wait for buses.
- Advertisement -
Sanwo-Olu Unveils 500 Mass Transit Buses, Launches Smart Ticketing System - Brand SpurSanwo-Olu Unveils 500 Mass Transit Buses, Launches Smart Ticketing System - Brand Spur

Subscribe to BrandSpur Ng

Subscribe for latest updates. Signup to best of brands and business news, informed analysis and opinions among others that can propel you, your business or brand to greater heights.

- Advertisement -

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Sanwo-Olu Unveils 500 Mass Transit Buses, Launches Smart Ticketing System - Brand SpurSanwo-Olu Unveils 500 Mass Transit Buses, Launches Smart Ticketing System - Brand Spur

Latest News

DEBx Medical Receives CE Mark Clearance and ISO 13485 Certification for Debrichem(R), a Novel Desiccant Gel for Chemical Debridement to Initiate Healing in Infected,...

  • Debrichem(R) offers a very effective, alternative approach to chronic wound care, initiating healing in more than 90 % of cases after one application[1]
  • CE mark and ISO 13485:2016 certification are important prerequisites for upcoming launches in markets worldwide
  • Chronic wounds affect 1 - 2 % of developed countries' populations,[2] unsuccessful treatment may lead to enlargement of the wound, bone involvement or in the worst case, amputation[3]
  • Debrichem soon to be launched in Europe, Hong Kong, South Africa, New Zealand and Australia
Read Also:  Never Take Any LinkedIn Connection for Granted...


ROTTERDAM, THE NETHERLANDS - EQS Newswire - 25 February 2021 - DEBx Medical, the Dutch medical technology company revolutionizing the management of chronic wounds, is excited to highlight today the successful completion of the CE conformity assessment procedure for Debrichem(R). The innovative topical agent offers a superior alternative to surgical debridement, the current standard of care. Debrichem can now carry the CE mark for a medical device class IIb and has also been awarded ISO 13485:2016 certification. These certifications endorse the quality and safety of Debrichem to treat a high unmet medical need and the strength of the DEBx Medical team to achieve this quickly even in such difficult times. DEBx Medical plans first to launch Debrichem in Europe, South Africa as well as Hong Kong, New Zealand and Australia through a network of distribution partners; other markets will follow. DEBx Medical has started consultations with the FDA about the pathway to approval earlier this year.

Debrichem is a topical desiccant gel for chemical wound debridement used for the treatment of chronic infected and/or necrotic wounds. This novel product desiccates (dehydrates) the biofilm and the pathogens in the wound bed, debriding the biofilm chemically instead of surgically. Surrounding healthy skin is not affected.[4] The data underlying the CE mark approval show that, after a one-time 60-second application, more than 90 % of wounds result in full granulation,1 an important step in the healing process.[5] Due to its fast action and applicability outside the surgery room, Debrichem can easily be integrated within standard wound care procedures.4

"Being granted the CE mark and ISO 13485 certification for Debrichem in less than two years after founding DEBx Medical is an exciting and important milestone. I am proud of our achievements and would like to thank the whole team involved in this huge effort," said Dr. Bertus Quint, founding CEO of DEBx Medical. "Chronic wounds are painful and debilitating and patients have very limited options for healing. With Debrichem, we set out to significantly improve this situation which is frustrating for healthcare professionals and patients alike. We believe that Debrichem has the potential to meaningfully improve health outcomes and quality of life for millions of patients worldwide."

"In my day-to-day work, I experience the patients' despair associated with chronic wounds and the doctors' frustration with their inability to provide patients long-term healing. With the current COVID-19 pandemic, the situation has been exacerbated: many of our patients are in high-risk groups - elderly, diabetic or chronic cardiovascular patients - who now cannot go to the hospital for their urgently needed treatment," said David L. Helfet, MD, Professor of Orthopaedic Surgery, Weill Cornell Medical College and Hospital for Special Surgery, New York Presbyterian Hospital. "The major advantage of Debrichem is that with a relatively simple, quick, one time application it destroys the biofilm. Removing the biofilm is absolute key to get chronic wounds to heal. Debrichem is an important step forward in the management of chronic wounds and will find its place in the standard of care in a very short time. It may even have the potential to become the new gold standard for debridement in chronic wound care."

Chronic wounds are defined as wounds that have not healed, at least in part, after 4 to 12 weeks.[6] Physiologically, healing of chronic wounds is corrupted, among other factors, by excess inflammation and a recurrent or persistent, if not drug-resistant, microbial infection, often in the biofilm on a wound bed.4 The current gold standard treatment, maintenance surgical debridement, is a painful procedure performed in a sterile environment. Surgical debridement does not reliably initiate healing of the wound but can be part of an extensive wound management program requiring patients to repeatedly come into the hospital. Not surprisingly, general quality of life is impaired in patients with chronic wounds.6 Chronic wounds are estimated to have a prevalence of up to 2 % in the general population.[7] The wound etiology has an impact on outcome, arterial ulcers and venous leg ulcers are notoriously difficult to heal. Chronic wounds are also a common comorbidity of diabetes,[8] 13 % of patients with diabetes in North America to 17 % in Belgium are suffering from chronic wounds.[9] The burden of chronic wounds to healthcare systems and society around the world is substantial, exacerbated by the high rate of amputation in especially diabetic patients which is close to 34 % for diabetic foot ulcers.8 In the UK alone, chronic wounds generated costs of GBP 5.6 bn in 2018. The total wound care costs in the UK increased annually by 8 - 9 % with chronic wounds accounting for the largest share.[10]

References
[1] Cogo A et al., J Wound Care 2020;29(Sup7b):63-64. https://doi.org/10.12968/jowc.2020.29.Sup7b.1
[2] Nussbaum SR et al., Value Health 2018;21:27-32. https://doi.org/10.1016/j.jval.2017.07.007
[3] Strohal R et al., J Wound Care 2013; 22 (Suppl. 1): S1-S52. https://doi.org/10.12968/jowc.2013.22.Sup1.S1
[4] Cogo A et al., Wounds 2021;33:1-8. https://www.woundsresearch.com/article/restarting-healing-process-chronic-wounds-using-novel-desiccant-prospective-case-series
[5]http://www.shieldhealthcare.com/community/popular/2015/12/18/how-wounds-heal-the-4-main-phases-of-wound-healing/
[6] Olsson M et al., Wound Repair Regen 2019;27(1):114-125. https://doi.org/10.1111/wrr.12683
[7] Martinengo L et al., Ann Epidemiol 2019;29:8-15. https://doi.org/10.1016/j.annepidem.2018.10.005
[8] McCosker L et al., Int Wound J 2019;16:84-95. https://doi.org/10.1111/iwj.12996
[9] Zhang P et al., Ann Med 2017;49:106-116. https://doi.org/10.1080/07853890.2016.1231932
[10] Guest JF et al., BMJ Open 2020;10:e045253. https://doi.org/10.1136/bmjopen-2020-045253


The issuer is solely responsible for the content of this announcement.


About Debrichem(R)

Debrichem(R) is a disruptive new treatment option to address the infection in chronic wounds. The topical agent offers a superior alternative to surgical debridement, the current standard of care. Debrichem has been demonstrated to remove the biofilm and the pathogens from the wound bed that disrupt the onset of the natural healing process. Out of the more than 1.000 patients treated so far, more than 90 % of chronic wounds started to heal after only one treatment with Debrichem.4 The product is applied in a fast and simple, non-invasive procedure. Healthcare professionals should always consider using local anesthetics when applying the treatment. Debrichem can be used outside a surgical environment which can be particularly useful in situations, such as during the COVID-19 pandemic, where patients cannot get to hospitals to undergo surgery, avoiding long-term complications like amputation. Debrichem will be sold through a worldwide network of distributors, with the first market launches expected in Q1 2021.


About DEBx Medical

DEBx Medical B.V. is a Dutch medical technology company dedicated to revolutionizing the management of chronic wounds by enabling their healing, thereby improving the outcomes for millions of patients. DEBx Medical supports doctors and their patients from diagnosis through treatment, follow-up care, and maintenance of a healthy wound bed. The Company focuses its pipeline on targeting pathogens that corrupt wound healing, aiming to deliver affordable and effective treatment approaches that can easily be applied and implemented in daily clinical practice. Debrichem(R), DEBx Medical's first product, received a CE mark in early 2021 and will be launched in markets around the world. Debrichem offers a disruptive approach to debridement that has been demonstrated to enable healing of chronic wounds in more than 90 % of cases.

Sanwo-Olu Unveils 500 Mass Transit Buses, Launches Smart Ticketing System - Brand Spur
- Advertisement -
BrandsPur Weekly Cartoons
- Advertisement -Sanwo-Olu Unveils 500 Mass Transit Buses, Launches Smart Ticketing System - Brand SpurSanwo-Olu Unveils 500 Mass Transit Buses, Launches Smart Ticketing System - Brand Spur